Stoke Therapeutics (NASDAQ:STOK) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK) in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a $35.00 target price on the stock. HC Wainwright also issued estimates for Stoke Therapeutics’ FY2024 earnings at ($2.51) EPS, FY2025 earnings at ($3.43) EPS, FY2026 earnings at ($2.57) EPS, FY2027 earnings at ($0.90) EPS and FY2028 earnings at $0.17 EPS.

Several other equities analysts also recently weighed in on the company. Cantor Fitzgerald reissued an overweight rating on shares of Stoke Therapeutics in a research report on Thursday, April 4th. Canaccord Genuity Group increased their target price on shares of Stoke Therapeutics from $18.00 to $21.00 and gave the company a buy rating in a research note on Tuesday, March 26th. Needham & Company LLC restated a buy rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Monday. Wedbush upped their price target on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the company an outperform rating in a report on Tuesday, March 26th. Finally, TD Cowen raised shares of Stoke Therapeutics from a market perform rating to an outperform rating in a research report on Tuesday, March 26th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Stoke Therapeutics presently has an average rating of Moderate Buy and a consensus target price of $20.57.

Stoke Therapeutics Price Performance

NASDAQ STOK opened at $11.77 on Tuesday. Stoke Therapeutics has a 1-year low of $3.35 and a 1-year high of $16.40. The business has a 50 day simple moving average of $10.30 and a two-hundred day simple moving average of $6.72. The stock has a market capitalization of $613.45 million, a PE ratio of -4.98 and a beta of 0.82.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Monday, March 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.02. The business had revenue of $2.80 million for the quarter, compared to analysts’ expectations of $3.70 million. On average, analysts anticipate that Stoke Therapeutics will post -2.28 EPS for the current fiscal year.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, CFO Stephen J. Tulipano sold 4,116 shares of the business’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $25,107.60. Following the completion of the sale, the chief financial officer now directly owns 20,746 shares of the company’s stock, valued at approximately $126,550.60. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 3,600,000 shares of the stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $11.60, for a total transaction of $41,760,000.00. Following the transaction, the insider now directly owns 10,843,681 shares in the company, valued at approximately $125,786,699.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Stephen J. Tulipano sold 4,116 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $25,107.60. Following the completion of the sale, the chief financial officer now directly owns 20,746 shares of the company’s stock, valued at approximately $126,550.60. The disclosure for this sale can be found here. Insiders sold 3,622,741 shares of company stock worth $41,935,115 in the last 90 days. 11.30% of the stock is owned by corporate insiders.

Institutional Trading of Stoke Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. State Board of Administration of Florida Retirement System bought a new position in Stoke Therapeutics in the first quarter worth about $141,000. Dorsey & Whitney Trust CO LLC acquired a new stake in Stoke Therapeutics in the 3rd quarter worth approximately $43,000. Sherbrooke Park Advisers LLC purchased a new stake in Stoke Therapeutics during the 3rd quarter worth approximately $48,000. SG Americas Securities LLC purchased a new position in shares of Stoke Therapeutics in the third quarter worth $53,000. Finally, BNP Paribas Financial Markets raised its stake in Stoke Therapeutics by 86.2% in the 1st quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock worth $193,000 after acquiring an additional 6,636 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.